These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26575424)

  • 1. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
    Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M
    Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways.
    Tong Q; Qing Y; Wu Y; Hu X; Jiang L; Wu X
    Toxicol Appl Pharmacol; 2014 Dec; 281(2):166-73. PubMed ID: 25111127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
    Weng WT; Huang SC; Ma YL; Chan HH; Lin SW; Wu JC; Wu CY; Wen ZH; Wang EM; Wu CL; Tai MH
    Biochim Biophys Acta; 2014 Jun; 1840(6):1850-60. PubMed ID: 24530634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.
    Dao P; Jarray R; Smith N; Lepelletier Y; Le Coq J; Lietha D; Hadj-Slimane R; Herbeuval JP; Garbay C; Raynaud F; Chen H
    Cancer Lett; 2014 Jun; 348(1-2):88-99. PubMed ID: 24657306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway.
    Huang KF; Huang XP; Xiao GQ; Yang HY; Lin JS; Diao Y
    Biomed Pharmacother; 2014 May; 68(4):455-61. PubMed ID: 24721321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells.
    Xing Y; Tu J; Zheng L; Guo L; Xi T
    Oncol Rep; 2015 Jan; 33(1):163-70. PubMed ID: 25376085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
    Yu Y; Cai W; Pei CG; Shao Y
    Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Pang X; Yi Z; Zhang X; Sung B; Qu W; Lian X; Aggarwal BB; Liu M
    Cancer Res; 2009 Jul; 69(14):5893-900. PubMed ID: 19567671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Water extract of Cinnamomum cassia suppresses angiogenesis through inhibition of VEGF receptor 2 phosphorylation.
    Kim EC; Kim HJ; Kim TJ
    Biosci Biotechnol Biochem; 2015; 79(4):617-24. PubMed ID: 25560253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.